-

10:19:17 PM

RHHBY Stock News

RHHBY - Roche Holding AG

06/29/22 1:00 AM

OTC : RHHBY

Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care

The BenchMark ULTRA PLUS tissue staining system, with optimised workflow, testing efficiency and environmentally sustainable features, enables pathologists to provide high-quality, time-critical results to doctors and patients. With laboratory diagnostics involved in more than two-thirds of

RHEA-AI

neutral

06/28/22 1:00 AM

OTC : RHHBY

Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics

The VENTANA DP 600 is Roche’s new, high-capacity slide scanner that creates high-resolution, digital images of stained tissue samples that help to diagnose cancer and determine a patient’s treatment. Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or

RHEA-AI

very positive

06/16/22 1:03 AM

OTC : RHHBY

Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options

Every year, over 604,000 women worldwide are diagnosed with cervical cancer and approximately 342,000 die from this preventable disease, caused by infection with Human Papillomavirus (HPV). 1 Nearly nine out of 10 women who die from cervical cancer live in low- and middle-income countries. 2 For

RHEA-AI

neutral

06/16/22 1:00 AM

OTC : RHHBY

Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease

Crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease For more than a decade Roche has been working in collaboration with Banner Alzheimer’s Institute, the University of Antioquia in Colombia and the National

RHEA-AI

neutral

06/15/22 11:45 AM

OTC : RHHBY

covid-19

Roche receives FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-19 and quantitatively measure viral load levels of COVID-19

The cobas SARS-CoV-2 Duo test combines the standard qualitative result of a traditional SARS-CoV-2 PCR test with a quantitative result, which measures the viral load of a patient suspected of COVID-19. Potential benefits of the cobas SARS-CoV-2 Duo test aim to help the healthcare community with

RHEA-AI

neutral

06/10/22 1:00 AM

OTC : RHHBY

Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting

Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatment U pdated data from phase III CLL14 study of

RHEA-AI

neutral

06/09/22 1:03 AM

OTC : RHHBY

fda approval

U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)

FoundationOne CDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solid tumours for whom treatment with Rozlytrek may be appropriate This approval marks the first and only companion diagnostic indication for Rozlytrek ,

RHEA-AI

very positive

06/09/22 1:00 AM

OTC : RHHBY

European Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer

In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive care Tecentriq is now the first and only cancer immunotherapy available for certain people with

RHEA-AI

very positive

06/08/22 1:00 AM

OTC : RHHBY

European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma

Lunsumio ® ( mosunetuzumab ) is the first CD20xCD3 T-cell engaging bispecific antibody available to treat the most common slow-growing form of non-Hodgkin lymphoma, follicular lymphoma (FL) Lunsumio represents a new type of immunotherapy that is a chemotherapy-free, off-the-shelf, fixed-duration

RHEA-AI

very positive

05/31/22 1:00 AM

OTC : RHHBY

fda approval

FDA approves Roche’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)

Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated with Evrysdi for at least one year were able to sit, stand and walk Prescribing information updated with FIREFISH data showing the majority of symptomatic babies treated with Evrysdi for at least two years could

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next